China Pharma Holdings Inc（CPHI）股票分析

AI 分析 of China Pharma Holdings Inc (CPHI)

賣出

Given the current price of $0.61 and an RSI of 29.837, which indicates the stock is oversold, it may seem like a buying opportunity. However, the stock has a staggering year-to-date change of -49.89% and a 1-year change of -60.98%, reflecting severe downward momentum. Furthermore, the gross margin is currently at 8.81%, which is low compared to industry standards, and the forward P/E ratio is 1.5581, suggesting potential undervaluation but also highlighting the risk of continued losses. The main risk is the high net income loss of $1,458,123 in Q2 2026, indicating ongoing financial struggles. Therefore, while there are indicators that could suggest a future rebound, the current financial health and performance metrics do not support a buy recommendation at this time.

估值指標

China Pharma Holdings Inc（CPHI）目前預期本益比為 1.56，5 年平均預期本益比為 0.26。

預期本益比

嚴重高估

5 年均值 P/E

0.26

目前P/E

1.56

高估

0.83

低估

-0.32

預期 EV/EBITDA

合理

5 年均值 EV/EBITDA

33.64

目前EV/EBITDA

-0.18

高估

269.99

低估

-202.72

預期股價營收比

高估

5 年均值 P/S

0.04

目前P/S

0.23

高估

0.19

低估

-0.10

Alphio AI 對 CPHI 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重（25 / 50 / 25），不構成保證。

樂

樂觀

樂觀 · 25%CPHI

$2.26

情境價格

基

基準

基準 · 50%CPHI

$2.13

情境價格

悲

悲觀

悲觀 · 25%CPHI

$2.05

情境價格

CPHI 常見問題 —— 由 Alphio AI 解答

China Pharma Holdings Inc is a company principally engaged in the development, manufacture, and marketing of pharmaceutical products for human use. The Company is mainly engaged in the development, manufacture, and marketing of pharmaceutical products for high-incidence and high-mortality diseases and medical conditions prevalent in the PRC. The Company's products include dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The Company's products and solutions are mainly applied in the treatment of various diseases and medical conditions. The Company mainly operates in the domestic market. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Given the current price of $0.61 and an RSI of 29.837, which indicates the stock is oversold, it may seem like a buying opportunity. However, the stock has a staggering year-to-date change of -49.89% and a 1-year change of -60.98%, reflecting severe downward momentum. Furthermore, the gross margin is currently at 8.81%, which is low compared to industry standards, and the forward P/E ratio is 1.5581, suggesting potential undervaluation but also highlighting the risk of continued losses. The main risk is the high net income loss of $1,458,123 in Q2 2026, indicating ongoing financial struggles. Therefore, while there are indicators that could suggest a future rebound, the current financial health and performance metrics do not support a buy recommendation at this time.